Aker BioMarine and the University of Illinois Chicago (UIC) are to team up to look into the modified form of two long-chain omega-3 fatty acids, with a view to improve its delivery to the eyes and brain.
The collaboration looks to support Aker’s new delivery platform, LYSOVETA that is based on lysophosphatidylcholine (LPC)-bound EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) derived from krill.
The complex enables EPA and DHA to pass through the blood-brain barrier and enter the brain as well as enriching the retina to improve ocular health.
“The LPC transporter allows EPA and DHA to enter the brain and the retina,” explains Papasani Subbaiah, professor of medicine, biochemistry and molecular genetics at the UIC College of Medicine.